{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:01:15Z","timestamp":1793944875017,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hypoimmunogenic universal induced pluripotent stemn (iPS) cells were generated through the targeted disruption of key genes, including human leukocyte antigen (\n                    <jats:italic>HLA<\/jats:italic>\n                    )-\n                    <jats:italic>A<\/jats:italic>\n                    ,\n                    <jats:italic>HLA-B<\/jats:italic>\n                    and\n                    <jats:italic>HLA-DR alpha<\/jats:italic>\n                    (\n                    <jats:italic>DRA<\/jats:italic>\n                    ), using the CRISPR\u2013Cas9 system. This approach aimed to minimize immune recognition and enhance the potential of iPS cells for allogeneic therapy. Heterozygous iPS cells were used for guide RNA design and validation to facilitate the knockout (KO) of the\n                    <jats:italic>HLA-A<\/jats:italic>\n                    ,\n                    <jats:italic>HLA-B<\/jats:italic>\n                    and\n                    <jats:italic>HLA-DRA<\/jats:italic>\n                    genes. The electroporation of iPS cells using the selected guide RNAs enabled the generation of triple-KO iPS cells, followed by single-cell cloning for clone selection. Clone A7, an iPS cell with targeted KOs of the\n                    <jats:italic>HLA-A<\/jats:italic>\n                    ,\n                    <jats:italic>HLA-B<\/jats:italic>\n                    and\n                    <jats:italic>HLA-DRA<\/jats:italic>\n                    genes, was identified as the final candidate. Messenger RNA analysis revealed robust expression of pluripotency markers, such as octamer-binding transcription factor 4, sex-determining region Y box 2, Kr\u00fcppel-like factor 4, Lin-28 homolog A and Nanog homeobox, while protein expression assays confirmed the presence of octamer-binding transcription factor 4, stage-specific embryonic antigen 4, Nanog homeobox and tumor rejection antigen 1\u201360. A karyotype examination revealed no anomalies, and three-germ layer differentiation assays confirmed the differentiation potential. After interferon gamma stimulation, the gene-corrected clone A7 lacked HLA-A, HLA-B and HLA-DR protein expression. Immunogenicity testing further confirmed the hypoimmunogenicity of clone A7, which was evidenced by the absence of proliferation in central memory T cells and effector memory T cells. In conclusion, clone A7, a triple-KO iPS cell clone that demonstrates immune evasion properties, retained its intrinsic iPS cell characteristics and exhibited no immunogenicity.\n                  <\/jats:p>","DOI":"10.1038\/s12276-025-01422-3","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:54:55Z","timestamp":1741920895000},"page":"686-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout"],"prefix":"10.1038","volume":"57","author":[{"given":"Juryun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyeong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-3463","authenticated-orcid":false,"given":"SeonJu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-1248","authenticated-orcid":false,"given":"Chang Pyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyerin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeowon","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeri Alice","family":"Rim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1422_CR1","doi-asserted-by":"publisher","first-page":"1005926","DOI":"10.3389\/fcell.2022.1005926","volume":"10","author":"K Thanaskody","year":"2022","unstructured":"Thanaskody, K. et al. MSCs vs. iPS cells: potential in therapeutic applications. Front. Cell Dev. Biol. 10, 1005926 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1422_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"1422_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrm3448","volume":"13","author":"M Bellin","year":"2012","unstructured":"Bellin, M., Marchetto, M. C., Gage, F. H. & Mummery, C. L. Induced pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13, 713\u2013726 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1422_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fimmu.2017.00645","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu, X., Li, W., Fu, X. & Xu, Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front. Immunol. 8, 645 (2017).","journal-title":"Front. Immunol."},{"key":"1422_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-018-0039-x","volume":"14","author":"RA Montgomery","year":"2018","unstructured":"Montgomery, R. A., Tatapudi, V. S., Leffell, M. S. & Zachary, A. A. HLA in transplantation. Nat. Rev. Nephrol. 14, 558\u2013570 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1422_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41581-022-00600-0","volume":"18","author":"C Duneton","year":"2022","unstructured":"Duneton, C., Winterberg, P. D. & Ford, M. L. Activation and regulation of alloreactive T cell immunity in solid organ transplantation. Nat. Rev. Nephrol. 18, 663\u2013676 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1422_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s42003-021-02237-4","volume":"4","author":"S Petrus-Reurer","year":"2021","unstructured":"Petrus-Reurer, S. et al. Immunological considerations and challenges for regenerative cellular therapies. Commun. Biol. 4, 798 (2021).","journal-title":"Commun. Biol."},{"key":"1422_CR8","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/ijms20184544","volume":"20","author":"T Nakamura","year":"2019","unstructured":"Nakamura, T., Shirouzu, T., Nakata, K., Yoshimura, N. & Ushigome, H. The role of major histocompatibility complex in organ transplantation-donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage. Int. J. Mol. Sci. 20, 4544 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1422_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tig.2020.01.008","volume":"36","author":"J Radwan","year":"2020","unstructured":"Radwan, J., Babik, W., Kaufman, J., Lenz, T. L. & Winternitz, J. Advances in the evolutionary understanding of MHC polymorphism. Trends. Genet. 36, 298\u2013311 (2020).","journal-title":"Trends. Genet."},{"key":"1422_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","volume":"15","author":"PA Roche","year":"2015","unstructured":"Roche, P. A. & Furuta, K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203\u2013216 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1422_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252\u2013258 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1422_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbmt.2008.06.014","volume":"14","author":"RA Bray","year":"2008","unstructured":"Bray, R. A. et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol. Blood Marrow Transplant 14, 45\u201353 (2008).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"1422_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/1-59745-049-9:157","volume":"333","author":"S Sheldon","year":"2006","unstructured":"Sheldon, S. & Poulton, K. HLA typing and its influence on organ transplantation. Transplant. Immunol. Methods Protoc. 333, 157\u2013174 (2006).","journal-title":"Transplant. Immunol. Methods Protoc."},{"key":"1422_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai, M. et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038\u20131046 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1422_CR15","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1422_CR16","doi-asserted-by":"publisher","first-page":"e1531","DOI":"10.1002\/term.2578","volume":"12","author":"YA Rim","year":"2018","unstructured":"Rim, Y. A. et al. Recent progress of national banking project on homozygous HLA-typed induced pluripotent stem cells in South Korea. J. Tissue Eng. Regen. Med. 12, e1531\u2013e1536 (2018).","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"1422_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nmeth.1591","volume":"8","author":"K Okita","year":"2011","unstructured":"Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409\u2013412 (2011).","journal-title":"Nat. Methods"},{"key":"1422_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR\u2013Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"1422_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732\u2013740 (2020).","journal-title":"Nat. Med."},{"key":"1422_CR20","doi-asserted-by":"publisher","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano, G. et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med. 14, eabq3010 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1422_CR21","doi-asserted-by":"publisher","first-page":"11810","DOI":"10.3390\/ijms241411810","volume":"24","author":"P Trionfini","year":"2023","unstructured":"Trionfini, P. et al. Hypoimmunogenic human pluripotent stem cells as a powerful tool for lLiver regenerative medicine. Int. J. Mol. Sci. 24, 11810 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1422_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2119\/molmed.2015.00235","volume":"22","author":"AK B\u00f6rger","year":"2016","unstructured":"B\u00f6rger, A. K. et al. Generation of HLA-universal iPSC-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol. Med. 22, 274\u2013285 (2016).","journal-title":"Mol. Med."},{"key":"1422_CR23","doi-asserted-by":"publisher","first-page":"e20220911","DOI":"10.1073\/pnas.2022091118","volume":"118","author":"T Deuse","year":"2021","unstructured":"Deuse, T. et al. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc. Natl Acad. Sci. USA 118, e20220911 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","volume":"26","author":"Y Kitano","year":"2022","unstructured":"Kitano, Y. et al. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol. Ther. Methods Clin. Dev. 26, 15\u201325 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1422_CR25","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41401-020-0452-0","volume":"41","author":"BC Geng","year":"2020","unstructured":"Geng, B. C. et al. A simple, quick, and efficient CRISPR\u2013Cas9 genome editing method for human induced pluripotent stem cells. Acta. Pharmacol. Sin. 41, 1427\u20131432 (2020).","journal-title":"Acta. Pharmacol. Sin."},{"key":"1422_CR26","doi-asserted-by":"publisher","first-page":"102551","DOI":"10.1016\/j.scr.2021.102551","volume":"56","author":"N Thongsin","year":"2021","unstructured":"Thongsin, N. & Wattanapanitch, M. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR\u2013Cas9 system. Stem Cell Res. 56, 102551 (2021).","journal-title":"Stem Cell Res."},{"key":"1422_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.stemcr.2019.11.011","volume":"14","author":"D Suzuki","year":"2020","unstructured":"Suzuki, D. et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity. Stem Cell Rep. 14, 49\u201359 (2020).","journal-title":"Stem Cell Rep."},{"key":"1422_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-022-02720-7","volume":"13","author":"C Song","year":"2022","unstructured":"Song, C. et al. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells. Stem Cell Res. Ther. 13, 48 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"1422_CR29","doi-asserted-by":"publisher","first-page":"e010239","DOI":"10.1161\/JAHA.118.010239","volume":"7","author":"S Mattapally","year":"2018","unstructured":"Mattapally, S. et al. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. J. Am. Heart Assoc. 7, e010239 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"1422_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat. Biomed. Eng. 5, 429\u2013440 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1422_CR31","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","volume":"95","author":"N Lee","year":"1998","unstructured":"Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199\u20135204 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1422_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.it.2017.01.009","volume":"38","author":"LMR Ferreira","year":"2017","unstructured":"Ferreira, L. M. R., Meissner, T. B., Tilburgs, T. & Strominger, J. L. HLA-G: at the interface of maternal-fetal tolerance. Trends. Immunol. 38, 272\u2013286 (2017).","journal-title":"Trends. Immunol."},{"key":"1422_CR33","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","volume":"218","author":"T Deuse","year":"2021","unstructured":"Deuse, T. et al. The SIRP\u03b1-CD47 immune checkpoint in NK cells. J. Exp. Med. 218, e20200839 (2021).","journal-title":"J. Exp. Med."},{"key":"1422_CR34","doi-asserted-by":"publisher","first-page":"662360","DOI":"10.3389\/fimmu.2021.662360","volume":"12","author":"C Flahou","year":"2021","unstructured":"Flahou, C., Morishima, T., Takizawa, H. & Sugimoto, N. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Front. Immunol. 12, 662360 (2021).","journal-title":"Front. Immunol."},{"key":"1422_CR35","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.isci.2020.101162","volume":"23","author":"W Zhao","year":"2020","unstructured":"Zhao, W. et al. Strategies for genetically engineering hypoimmunogenic universal pluripotent stem cells. iScience 23, 101162 (2020).","journal-title":"iScience"},{"key":"1422_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Targeted disruption of HLA genes via CRISPR\u2013Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566\u2013578 (2019).","journal-title":"Cell Stem Cell"},{"key":"1422_CR37","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han, X. et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl Acad. Sci. USA 116, 10441\u201310446 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1422_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0190-2","author":"Y Jang","year":"2019","unstructured":"Jang, Y. et al. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Exp. Mol. Med. https:\/\/doi.org\/10.1038\/s12276-018-0190-2 (2019).","journal-title":"Exp. Mol. Med."},{"key":"1422_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s12015-020-10113-7","volume":"17","author":"A Kim","year":"2021","unstructured":"Kim, A. et al. Off-the-shelf, immune-compatible human embryonic stem cells generated via CRISPR-mediated genome editing. Stem Cell Rev. Rep. 17, 1053\u20131067 (2021).","journal-title":"Stem Cell Rev. Rep."},{"key":"1422_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nprot.2016.153","volume":"12","author":"NJ Palpant","year":"2017","unstructured":"Palpant, N. J. et al. Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. Nat. Protoc. 12, 15\u201331 (2017).","journal-title":"Nat. Protoc."},{"key":"1422_CR41","doi-asserted-by":"publisher","first-page":"D423","DOI":"10.1093\/nar\/gku1161","volume":"43","author":"J Robinson","year":"2015","unstructured":"Robinson, J. et al. The IPD and IMGT\/HLA database: allele variant databases. Nucleic Acids Res. 43, D423\u2013D431 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1422_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s40778-022-00221-0","volume":"8","author":"TB Meissner","year":"2022","unstructured":"Meissner, T. B., Schulze, H. S. & Dale, S. M. Immune editing: overcoming immune barriers in stem cell transplantation. Curr. Stem Cell Rep. 8, 206\u2013218 (2022).","journal-title":"Curr. Stem Cell Rep."},{"key":"1422_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41232-020-00132-9","volume":"40","author":"K Koga","year":"2020","unstructured":"Koga, K., Wang, B. & Kaneko, S. Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflamm. Regen. 40, 23 (2020).","journal-title":"Inflamm. Regen."},{"key":"1422_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01847-9","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/s13287-020-01847-9 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"1422_CR45","doi-asserted-by":"publisher","first-page":"109538","DOI":"10.1016\/j.celrep.2021.109538","volume":"36","author":"AV Parent","year":"2021","unstructured":"Parent, A. V. et al. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538 (2021).","journal-title":"Cell Rep."},{"key":"1422_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60466-9","volume":"10","author":"HY Jo","year":"2020","unstructured":"Jo, H. Y. et al. Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives. Sci. Rep. 10, 3939 (2020).","journal-title":"Sci. Rep."},{"key":"1422_CR47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1365-2567.1997.00258.x","volume":"91","author":"P Keskinen","year":"1997","unstructured":"Keskinen, P., Ronni, T., Matikainen, S., Lehtonen, A. & Julkunen, I. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. Immunology 91, 421\u2013429 (1997).","journal-title":"Immunology"},{"key":"1422_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.117.306290","volume":"117","author":"P Abrahimi","year":"2015","unstructured":"Abrahimi, P. et al. Efficient gene disruption in cultured primary human endothelial cells by CRISPR\u2013Cas9. Circ. Res. 117, 121\u2013128 (2015).","journal-title":"Circ. Res."},{"key":"1422_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/2211-5463.12854","volume":"10","author":"A Maenaka","year":"2020","unstructured":"Maenaka, A. et al. Interferon-\u03b3-induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG-CoA reductase. FEBS Open Bio 10, 927\u2013936 (2020).","journal-title":"FEBS Open Bio"},{"key":"1422_CR50","doi-asserted-by":"publisher","first-page":"447508","DOI":"10.3389\/fimmu.2019.01081","volume":"10","author":"A Couture","year":"2019","unstructured":"Couture, A. et al. HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front. Immunol. 10, 447508 (2019).","journal-title":"Front. Immunol."},{"key":"1422_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ni.2038","volume":"12","author":"M Pepper","year":"2011","unstructured":"Pepper, M. & Jenkins, M. K. Origins of CD4+ effector and central memory T cells. Nat. Immunol. 12, 467\u2013471 (2011).","journal-title":"Nat. Immunol."},{"key":"1422_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nri3227","volume":"12","author":"KJ Wood","year":"2012","unstructured":"Wood, K. J., Bushell, A. & Hester, J. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12, 417\u2013430 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1422_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 16, 115\u2013130 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1422_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.stemcr.2016.08.010","volume":"7","author":"S Sugita","year":"2016","unstructured":"Sugita, S. et al. Successful transplantation of retinal pigment epithelial cells from MHC homozygote iPSCs in MHC-matched models. Stem Cell Rep 7, 635\u2013648 (2016).","journal-title":"Stem Cell Rep"},{"key":"1422_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36408-0","volume":"14","author":"K Abe","year":"2023","unstructured":"Abe, K. et al. Engraftment of allogeneic iPS cell-derived cartilage organoid in a primate model of articular cartilage defect. Nat. Commun. 14, 804 (2023).","journal-title":"Nat. Commun."},{"key":"1422_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41536-020-00100-4","volume":"5","author":"J Deinsberger","year":"2020","unstructured":"Deinsberger, J., Reisinger, D. & Weber, B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. npj Regen. Med. 5, 15 (2020).","journal-title":"npj Regen. Med."},{"key":"1422_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00125-8","author":"R Otsuka","year":"2020","unstructured":"Otsuka, R., Wada, H., Murata, T. & Seino, K. I. Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflamm. Regen. https:\/\/doi.org\/10.1186\/s41232-020-00125-8 (2020).","journal-title":"Inflamm. Regen."},{"key":"1422_CR58","doi-asserted-by":"publisher","first-page":"e15315","DOI":"10.15252\/emmm.202115315","volume":"15","author":"DH McKenna","year":"2023","unstructured":"McKenna, D. H. & Perlingeiro, R. C. R. Development of allogeneic iPS cell-based therapy: from bench to bedside. EMBO Mol. Med. 15, e15315 (2023).","journal-title":"EMBO Mol. Med."},{"key":"1422_CR59","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1172\/JCI80575","volume":"125","author":"E Neofytou","year":"2015","unstructured":"Neofytou, E., O\u2019Brien, C. G., Couture, L. A. & Wu, J. C. Hurdles to clinical translation of human induced pluripotent stem cells. J. Clin. Invest. 125, 2551\u20132557 (2015).","journal-title":"J. Clin. Invest."},{"key":"1422_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.08.001","author":"JL Dashnau","year":"2023","unstructured":"Dashnau, J. L. et al. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2022.08.001 (2023).","journal-title":"Cytotherapy"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01422-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T23:42:04Z","timestamp":1743723724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01422-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01422-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4354435\/v1","asserted-by":"object"}]},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}